Vera Therapeutics, Inc. Class A Common Stock
Follow $VERA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $VERA by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is VERA moving today?
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
VERA overview
Related filings and maps
Congress activity in VERA
No receipt-qualified Congressional disclosure is present for VERA in the cached public ledger.
VERA contract awards, year to date.
Public federal awards linked to this ticker.
VERA lobbying filings, year to date.
Registered lobbying filings matched to Vera Therapeutics, Inc. Class A Common Stock.